Table 2.
Parameters of adherence and graft function during two-year periods of observation
| Adolescent group | Transitioned group | Young adult group (n=26) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Graft loss (n=22) | P1 | Combined# (n=71) | P2 | before the transfer (n=25) | P3 | after the transfer (n=25) | P4 | ||
| Median serum tacrolimus CV% [IQR] | 46.7 [41.4 to 58.4] | 0.07 | 44.1 [29.9 to 50.4] | 0.32 | 42.9 [31.4 to 51.0] | 0.62 | 40.4 [29.9 to 50.4] | 0.98 | 38.5 [26.8 to 53.1] |
| Median frequency of serum tacrolimus monitoring, n per year [IQR] | 14.3 [11.2 to 18.2] | 0.004 | 7.7 [6.0 to 13.2] | 0.02 | 6.3 [5.0 to 8.1] | 0.61 | 5.5 [3.0 to 10.5] | 0.15 | 7.5 [4.4 to 8.0] |
| Non-adherent patients*, n (%) | 15 (68%) | 0.01 | 29(41%) | 0.43 | 8 (32%) | 1.0 | 8 (32%) | 1.0 | 9 (35%) |
| Median percent of low serum tacrolimus levels, [IQR] | 15.7 [0.0 to 23.3] | 0.04 | 6.6 [0.0 to 18.7] | 0.30 | 0.0 [0.0 to 18.6] | 0.59 | 0.0 [0.0 to 15.7] | 0.60 | 0.0 [0.0 to 11.5] |
| Median frequency of clinic visits, n per year [IQR] | 10.2 [6.9 to 13.8] | 0.003 | 6.2 [4.5 to 9.0] | 0.03 | 5.5 [3.8 to 6.7] | 0.75 | 4.7 [2.3 to 6.7] | 0.27 | 4.3 [2.9 to 8.0] |
| Median frequency of inpatient admissions, n per year [IQR] | 1.4 [0.5 to 3.0] | 0.06 | 0.5 [0.0 to 1.6] | 0.20 | 0.5 [0.0 to 1.0] | 0.95 | 0.25 [0.0 to 1.0] | 0.66 | 0.0 [0.0 to 1.0] |
| 4-year graft survival**, n (%) | 49(69%) | 0.07 | 22 (88%) | 0.72 | 22 (85%) | ||||
| Median serum creatinine [IQR] | 2.5 [1.6 to 3.5] | <0.0001 | 1.3 [1.13 to 2.0] | 0.71 | 1.2 [1.1 to 1.5] | 0.009 | 1.5 [1.1 to 2.3] | 0.58 | 1.4 [1.1 to 1.8] |
| Median systolic blood pressure [IQR] | 126 [121 to 136] | 0.17 | 123 [115 to 131] | 0.28 | 119 [113 to 130] | 0.11 | 124 [115 to 140] | 0.27 | 120 [110 to 130] |
| Median diastolic blood pressure [IQR] | 74 [68 to 82] | 0.92 | 73 [68 to 78] | 0.001 | 73 [69 to 78] | 0.048 | 79 [76 to 86] | 0.25 | 77 [70 to 82] |
| Median serum tacrolimus CV% [IQR] | 46.7 [41.4 to 58.4] | 0.07 | 44.1 [29.9 to 50.4] | 0.32 | 42.9 [31.4 to 51.0] | 0.62 | 40.4 [29.9 to 50.4] | 0.98 | 38.5 [26.8 to 53.1] |
#
combined adolescent group includes active adolescent group, graft loss adolescent group and transitioned group (before the transfer)
*
Based on the percent of low serum tacrolimus levels
**
From the beginning of observation for the combined adolescent group, from transplant date for the young adult group, from the date of transfer for the transitioned group
1
adolescent graft loss group vs. transitioned group before transfer
2
combined group vs. transitioned group after transfer
3
transitioned group before vs. after transfer
4
young adult group vs. transitioned group after transfer